359 related articles for article (PubMed ID: 31598114)
21. Patient-derived tumour xenografts for breast cancer drug discovery.
Cassidy JW; Batra AS; Greenwood W; Bruna A
Endocr Relat Cancer; 2016 Dec; 23(12):T259-T270. PubMed ID: 27702751
[TBL] [Abstract][Full Text] [Related]
22. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
[TBL] [Abstract][Full Text] [Related]
23. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
24. Novel applications of molecular imaging to guide breast cancer therapy.
Edmonds CE; O'Brien SR; Mankoff DA; Pantel AR
Cancer Imaging; 2022 Jun; 22(1):31. PubMed ID: 35729608
[TBL] [Abstract][Full Text] [Related]
25. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
26. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
27. Role of positron emission tomography/computed tomography in breast cancer.
Bourgeois AC; Warren LA; Chang TT; Embry S; Hudson K; Bradley YC
Radiol Clin North Am; 2013 Sep; 51(5):781-98. PubMed ID: 24010906
[TBL] [Abstract][Full Text] [Related]
28. Development of
Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
[TBL] [Abstract][Full Text] [Related]
29. Imaging of HER2 with [
Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
[No Abstract] [Full Text] [Related]
30. [Breast cancer classification is evolving].
Penault-Llorca F
Biol Aujourdhui; 2014; 208(4):251-9. PubMed ID: 25840451
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer: early diagnosis and effective treatment by drug delivery tracing.
Shamsi M; Pirayesh Islamian J
Nucl Med Rev Cent East Eur; 2017; 20(1):45-48. PubMed ID: 28218347
[TBL] [Abstract][Full Text] [Related]
32. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
33. 18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report.
Riccardi F; Mocerino C; Barbato C; Vitale MG; Carrillo G; Trunfio M; Minelli S; Cartenì G
Tumori; 2013; 99(6):257e-60e. PubMed ID: 24503798
[TBL] [Abstract][Full Text] [Related]
34. Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
Leboeuf R; Bénard F; Langlois MF
Clin Nucl Med; 2006 Jul; 31(7):382-5. PubMed ID: 16785803
[TBL] [Abstract][Full Text] [Related]
35. Molecular imaging using PET and SPECT for identification of breast cancer subtypes.
Liu H; Chen Y; Wu S; Song F; Zhang H; Tian M
Nucl Med Commun; 2016 Nov; 37(11):1116-24. PubMed ID: 27438531
[TBL] [Abstract][Full Text] [Related]
36. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
37. Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):557-559. PubMed ID: 32342707
[No Abstract] [Full Text] [Related]
38. Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer.
Clark AS; McDonald E; Lynch MC; Mankoff D
Oncology (Williston Park); 2014 May; 28(5):424-30. PubMed ID: 25004657
[TBL] [Abstract][Full Text] [Related]
39. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
40. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
J Exp Clin Cancer Res; ; . PubMed ID: 31299997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
